Behind the science
Addressing Long-Standing Barriers to Adult Immunization
With our COiMMUNITY Initiative, we are designing a more systematic, collaborative and equitable approach to help increase vaccination rates.
Investors
We announced our third quarter 2023 results on Wednesday 1 November.
Press releases
- US FDA accepts for priority review GSK’s application for an expanded indication of Jemperli (dostarlimab-gxly) plus chemotherapy to include all adult patients with primary advanced or recurrent endometrial cancer
- New long-term data show SHINGRIX continues to provide high protection against shingles in adults aged 50 and over for more than a decade
- GSK’s 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA
Choose your path
By bringing outstanding people together in an inclusive environment to do work that matters, we can impact the world’s health.
GSK Global links
Visit our Global site for additional features